Evidence map›Paper›PMID 15895193›Full record

ArticleWorld journal of surgery2005

Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up.

Stanley P L Leong, Mohammed Kashani-Sabet, Renee A Desmond, Robert P Kim, Dennis H Nguyen, Kensho Iwanaga, Patrick A Treseler, Robert E Allen, Eugene T Morita, Yuting Zhang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of surgery, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 47 citations in OpenAlex.

  1. Sentinel Lymph Node Biopsy in Melanoma: Overview and Updates.International journal of molecular sciences · 2025
    Review
  2. Sentinel Lymph Node Biopsy in Head and Neck Melanoma: Long-term Outcomes, Prognostic Value, Accuracy, and Safety.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2020
    Article
  3. Article
  4. Article
  5. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010
    Article
  6. Sentinel lymph node biopsy in melanoma.Current treatment options in oncology · 2008
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Stanley P L LeongDepartment of Surgery, University of California, San Francisco, Medical Center at Mount Zion and CSF Comprehensive Cancer Center, 1600 Divisadero Street, Box 1674, San Francisco, California 94143, USA. leongs@surgery.ucsf.edu
Mohammed Kashani-Sabet
Renee A Desmond
Robert P Kim
Dennis H Nguyen
Kensho Iwanaga
Patrick A Treseler
Robert E Allen
Eugene T Morita
Yuting Zhang
Richard W Sagebiel
Seng-Jaw Soong
University of California San Francisco Medical Center · USUniversity of Alabama at Birmingham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selective sentinel lymphadenectomy (SSL) following preoperative lymphoscintigraphy is the most significant recent advance in the management of patients with primary melanoma. This study evaluates the prognostic value of sentinel lymph node (SLN) status and other risk factors in predicting survival and recurrence in patients with primary cutaneous melanoma. From October 1993 to July 1998 a series of 412 patients with primary invasive melanoma underwent SSL at the UCSF/ Mt. Zion Melanoma Center. The outcome of 363 evaluable patients is summarized in this study. The factors related to survival and disease recurrence were analyzed by Cox proportional hazard regression models. The overall incidence of patients with positive SLNs was 18%. Over a median follow-up of 4.8 years, the overall mortality rate in patients with primary cutaneous melanoma was 18.7%, and 74 recurrences occurred (20.4%). Mortality was significantly related to SLN status [HR = 2.06; 95% Confidence interval (CI) 1.18, 3.58], angiolymphatic invasion (HR = 2.21; 95% CI 1.08, 4.55), ulceration (HR = 1.79; 95% CI 1.02, 3.15), mitotic index (HR =1.38; 95% CI 1.01, 1.90), and tumor thickness (HR = 2.20, 95% CI 1.21, 3.99). Factors significantly related to disease-free survival included SLN status (HR = 2.09; 95% CI 1.31, 3.34), tumor thickness (HR = 1.89; 95%. CI 1.20,2.98), and age (HR= 1.26 95% CI 1.08, 1.47). SLN status was the most significant factor for melanoma recurrence and death. Other important predictors include tumor thickness, ulceration, lymphatic invasion, and mitotic index.

Indexed as

AdultAgedFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMelanomaMiddle AgedNeoplasm Recurrence, LocalPrognosisRisk FactorsSentinel Lymph Node BiopsySkin NeoplasmsSurvival RateTime Factors

Identifiers

PMID15895193
OpenAlexW2078773638

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.